Drug Profile

ARCT 154

Alternative Names: ARCT-154; Kostaive; VBC-COV19-154

Latest Information Update: 22 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arcturus Therapeutics
Developer Arcturus Therapeutics; Meiji Seika Pharma; Vinbiocare Biotechnology
Class COVID-19 vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Marketed COVID 2019 infections

Most Recent Events

12 May 2025 Arcturus Therapeutics plans to file BLA filing in US in quarter three 0f 2025
12 May 2025 Arcturus Therapeutics plans MAA filing for KOSTAIVE® in the United Kingdom in quarter two of 2025
30 Apr 2025 Pharmacodynamics data from preclinical trial in COVID-20219 infection released by Meiji Seika Pharma, before April 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com